Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...
Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...
Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...
Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...
Lower serum levels of both vitamin D and zinc were associated with an increased risk of alopecia areata, but no significant difference in alopecia areata risk was observed for serum copper levels.
Please provide your email address to receive an email when new articles are posted on . Alopecia areata was classified as early-onset, severe or prolonged. Each additional atopic comorbidity ...
The five main types of alopecia are cicatricial alopecia, androgenic alopecia, alopecia areata, alopecia totalis, and telogen effluvium. An autoimmune condition known as alopecia areata affects ...
In June 2023, Pfizer's LITFULOTM (Ritlecitinib) for Adults and Adolescents with Severe Alopecia Areata received FDA approval. The medication, known by the brand name Litfulo, has been approved for ...
Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is unpredictable and varies greatly from individual to individual.
The illness may affect anyone, male or female, of any age. The five main types of alopecia are cicatricial alopecia, androgenic alopecia, alopecia areata, alopecia totalis, and telogen effluvium. An ...